Search Results

Data Published on Corindus CorPath 200 Robotic PCI System

April 15, 2011—Findings from a first-in-human study that aimed to evaluate the safety and feasibility of the CorPath 200 remote-controlled, robotic angioplasty system (Corindus, Inc., Natick, MA) in the delivery and manipulation of coronary guidewires, balloons, and stents in patients undergoing elective percutaneous coronary intervention (PCI) were published by Juan F. Granada, MD, et al in the Journal of the American College of Cardiology: Cardiovascular Interventions (2011;4:460–465).

Corindus Announces First Results for CorPath 200 System

September 20, 2010—Corindus Vascular Robotics (Natick, MA) announced the results of the first clinical study to evaluate the safety and technical efficacy of the CorPath 200 system in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary intervention (PCI) procedures.

Thoratec Begins HeartMate PHP CE Mark Trial

August 6, 2014—Thoratec Corporation announced that it has commenced the CE Mark clinical trial for its HeartMate PHP percutaneous heart pump.

ACC and CRF Create the Martin B. Leon Center for Cardiovascular Transformation

October 14, 2020—The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) announced that they are partnering to create the Martin B. Leon Center for Cardiovascular Transformation to foster the best ideas, encourage innovative research, and deliver transformative solutions to some of the biggest cardiovascular care challenges.

Biomodex Introduces Transseptal Puncture Training Solution

January 14, 2021—Biomodex announced the launch of the company’s Transseptal Puncture Training solution.

AATS and CRF Partner on New York Valves Meeting

April 19, 2024—The American Association for Thoracic Surgery (AATS) and the Cardiovascular Research Foundation (CRF) announced a strategic partnership for CRF’s New York Valves 2024: The Structural Heart Summit.

Safety and Feasibility Data Presented for Amaranth's Fortitude Bioresorbable Scaffold

October 28, 2013—Amaranth Medical (Mountain View, CA) announced the presentation of positive 6-month angiographic results from its first-in-human study of the Fortitude non–drug-eluting bioresorbable scaffold for patients undergoing percutaneous coronary intervention (PCI) with single coronary lesions.

AHA and CRF Announce Educational Alliance

August 15, 2022—The American Heart Association (AHA) and the Cardiovascular Research Foundation (CRF) announced a new alliance intended to strengthen and expand educational opportunities focused on advancing the latest research in cardiovascular disease and interventional therapies.

Jenscare’s Lux-Valve Plus Evaluated in 1-Year TRAVEL II Study Data

November 8, 2024—Jenscare Scientific Co., Ltd., which is based in Ningbo, China, recently announced the 1-year outcomes from the TRAVEL II trial of Lux-Valve Plus, the company’s transcatheter tricuspid valve replacement (TTVR) system.